Summary
Our AFC regimen was originally developed to treat superficial bladder tumors. It consists of a daily intravesical administration of 20 mg Adriamycin (ADM) and 200 mg Cytosine arabinoside (CA) dissolved in 20 ml of sterilized distilled water, simultaneously with a daily rectal suppository of 750 mg tegafur (Futraful) for a total of 20 applications.
Our study demonstrated the following characteristics of the AFC modality: (1) It is simple; (2) it is completed in 3 weeks, which is shorter than conventional bladder instillation therapy; (3) the effective rate is reasonable (70%); (4) no local side-effects were observed because the concentrations of ADM and CA were low; (5) interruption of therapy was unnecessary, because whatever general side-effects were caused, they disappeared within several days of completion of treatment.
Similar content being viewed by others
References
Araki H, Mishina T, Miyakoda K, Fujiwara T, Kobayashi T (1982) Cytosine arabinoside bladder instillation therapy for bladder tumors. Tohoku J Exp Med 136: 23
Harmer MH (1978) In: TNM classification of malignant tumors, 3rd edn. WHO, Geneva, p 113
Mishina T, Fujiwara T, Miyakoda K, Araki H, Kobayashi T, Saitoh M, Watanabe H (1979) Adriamycin instillation therapy for bladder tumors. Tohoku J Exp Med 127: 339
Mishina T, Watanabe H, Kobayashi T, Maegawa M, Nakao M, Nakagawa S (1983) Clinical application of Tegafur suppository for bladder tumors, (in press)
Miyakoda K, Mishina T, Araki H, Fujiwara T, Kobayashi T, Watanabe H (1978) Basic study on the application of FT-207 suppository for urogenital malignant tumors. Acta Urologica Japonica 24: 55
Ozaki Y (1977) Bladder instillation of Adriamycin in the treatment of bladder tumors. 1. Clinical results. Jpn J Urol 68: 934
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mishina, T., Kobayashi, T., Maegawa, M. et al. Development and clinical application of an AFC regimen (Adriamycin, Futraful, Cytosine arabinoside) for superficial bladder tumors. Cancer Chemother. Pharmacol. 11 (Suppl 1), S89–S90 (1983). https://doi.org/10.1007/BF00256727
Issue Date:
DOI: https://doi.org/10.1007/BF00256727